A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

Status:
RECRUITING

Trial end date:
2027-11-30

Target enrollment:

Participant gender:

The primary purpose of this study is to evaluate the efficacy of filgotinib in establishing clinical remission at Week 10 or 22.

PHASE4

Eisai Korea Inc.

Gilead Sciences